

# Table of Contents

---

<b>About the Author</b> .....	vii
<b>Table of Chapters</b> .....	ix
<b>Acknowledgments</b> .....	xix
<b>Introduction</b> .....	xxi

## **Chapter 1 Learning from Past and Current Pandemics**

§ 1:1	Drawing Lessons from Prior Events .....	1-1
§ 1:2	Classical Pandemics .....	1-2
§ 1:3	SARS .....	1-2
§ 1:4	Middle East Respiratory Syndrome .....	1-3
§ 1:5	Swine Flu .....	1-3
§ 1:6	Ebola .....	1-3
§ 1:7	Zika .....	1-4
§ 1:8	How Pandemic Experiences Have Taught Lessons .....	1-4
§ 1:9	Statistics for USA COVID-19 Cases .....	1-5
§ 1:10	Confirmed and Probable Counts .....	1-5
§ 1:11	Global Health Statistics .....	1-6

## **Chapter 2 Medical Workplace Challenges from COVID-19**

§ 2:1	COVID-19's Threat to Medical Workers .....	2-1
§ 2:2	How Is the Medical Hierarchy Organized for Coronavirus Responses? .....	2-2
§ 2:2.1	Healthcare Decision Making .....	2-2
§ 2:2.2	Hospitals .....	2-3
§ 2:2.3	Controls on Contract Healthcare Workers .....	2-4
§ 2:2.4	Credentialing .....	2-4
[A]	Government Licensure .....	2-5
[B]	Credentials Committee Gatekeepers .....	2-6
§ 2:3	Nursing Homes .....	2-7
§ 2:4	Telemedicine As a Tool for Evaluating Patients and Shielding the Provider .....	2-8
§ 2:4.1	Telehealth Waivers from the Centers for Medicare & Medicaid Services (CMS) .....	2-9
§ 2:4.2	HIPAA Flexibility During COVID-19 .....	2-10

§ 2:5	Adequacy of Supplies of Healthcare Protective Equipment.....	2-11
§ 2:6	Nursing Homes and Long-Term Care: Shortages Can Be Fatal .....	2-11
§ 2:7	“Standard of Care” and Malpractice Claims in the COVID-19 Context .....	2-12
§ 2:8	Healthcare Worker Complaints About Working Conditions.....	2-14

**Chapter 3     Shutdowns, Layoffs and Furloughs**

§ 3:1	Types of Workplace Interruptions Related to COVID-19 Infections .....	3-1
§ 3:2	New Norms of Layoff and Disconnection of People .....	3-2
§ 3:3	Changing Worksites to Limit Potential Virus-Transmission Risks .....	3-3
§ 3:4	Employment Interruption Mandated by Government Orders.....	3-3
§ 3:5	Unionized Workers and Layoffs .....	3-4
§ 3:6	Emergency Powers .....	3-4
§ 3:7	Shutdown for Temporary Decontamination of Site.....	3-5
§ 3:8	Shutdown for Loss of Customer Access .....	3-5
§ 3:9	Shutdown for Government-Related Supply Chain Problems.....	3-6
§ 3:10	Agricultural Work Reductions Related to COVID-19 Disruption of the Food Supply Chains.....	3-6
§ 3:11	Unemployment Compensation Under 2020 CARES Legislation.....	3-6

**Chapter 4     Overview of Workplace Impacts of Responses to COVID-19**

§ 4:1	Overview of Employment Effects—Statistics of Impacts.....	4-1
§ 4:2	Worker Impacts .....	4-3
§ 4:3	Response Functions: Engineering and Administrative Controls—Separation and Redesign of Workstations and Workflow.....	4-4
§ 4:3.1	Workplace Risk Levels .....	4-5
§ 4:3.2	Elimination and Substitution.....	4-7
§ 4:3.3	Engineering Controls .....	4-8
§ 4:4	Administrative Controls .....	4-9
§ 4:5	Workplace Discipline for Not Observing Protective Steps .....	4-13
§ 4:6	The Impact of Vaccination on Workplace Responses .....	4-13

## **Chapter 5 COVID-19, Contracts and Frustration Defenses**

§ 5:1	How Will COVID-19 Challenges Impact Business Clients? .....	5-1
§ 5:2	How Does the “Force Majeure” Contract Clause Apply?.....	5-2
§ 5:3	Foreseeability.....	5-3
§ 5:4	Force Majeure Clauses in the Future .....	5-4
§ 5:5	Impossibility.....	5-5
§ 5:6	Impracticability .....	5-7
§ 5:7	Frustration of Purpose .....	5-8
§ 5:7.1	Examples of a Frustration Defense.....	5-8
§ 5:8	Statutory Law .....	5-9
§ 5:8.1	State Actions.....	5-9
§ 5:8.2	Federal Action.....	5-10

## **Chapter 6 Overview of Workplace Liability Claims**

§ 6:1	Overview of Employment Effects of the Virus Globally.....	6-1
§ 6:2	Worker Impacts .....	6-2
§ 6:3	Workplace Discipline for Not Observing Protective Operating Procedures.....	6-5
§ 6:4	Workplace Liability for Contracting COVID-19.....	6-6
§ 6:5	Workplace Responses: Occupational Safety and Health Administration .....	6-7
§ 6:6	Resources for Workplace Compliance Programs.....	6-10
§ 6:7	Asymptomatic and Pre-Symptomatic Infection .....	6-10
§ 6:8	Core Principles of Case Investigation and Contact Tracing.....	6-11
§ 6:8.1	Effective Case Investigation and Contact Tracing Require Specialized Skills .....	6-12
§ 6:8.2	Key Considerations for Contact Tracing for COVID-19.....	6-13

## **Chapter 7 Public-Sector Workplaces**

§ 7:1	Public Workers at Risk.....	7-1
§ 7:2	Consider the Front-Line Roles of Public Employees .....	7-2
§ 7:3	First Responder Exposure Concerns.....	7-2
§ 7:4	Staffing and Funding of Public Agencies After COVID-19.....	7-3
§ 7:5	Public-Sector Labor Relations .....	7-3

**Chapter 8 Lockdown, Isolation, Quarantine and Travel Restrictions**

§ 8:1 Lockdown and Quarantine ..... 8-1  
 § 8:2 Historic Powers of Quarantine..... 8-2  
 § 8:3 Quarantine ..... 8-2  
 § 8:4 Isolation ..... 8-2  
 § 8:5 An Employee Who Is Positive for COVID-19  
 Should Isolate or Quarantine..... 8-3  
 § 8:6 Employees Without Symptoms but Who Have Been  
 Exposed to COVID-19..... 8-4  
 § 8:7 International Travel Controls ..... 8-5  
     § 8:7.1 Types of Notices..... 8-5  
     § 8:7.2 Requirements When Returning from  
     International Travel ..... 8-6

**Chapter 9 Understanding Testing Issues for COVID-19**

§ 9:1 Types of Tests ..... 9-1  
 § 9:2 The Potential Legal Issues from Testing..... 9-2  
 § 9:3 Viral Tests..... 9-2  
 § 9:4 Antibody Tests..... 9-4  
 § 9:5 Evaluating the Test Options—Sensitivity and  
 Specificity ..... 9-6  
 § 9:6 Roles of the FDA ..... 9-6  
 § 9:7 Risks of Fraud..... 9-7  
 § 9:8 Flaws in Results..... 9-7  
 § 9:9 Tests for Management of COVID-19 Patients..... 9-8  
 § 9:10 Environmental Testing..... 9-8  
     § 9:10.1 Quantitative Methods for Evaluating  
     Environmental Hygiene ..... 9-8  
     § 9:10.2 Objective Methods for Evaluating  
     Environmental Hygiene ..... 9-9  
 § 9:11 Conclusion ..... 9-11

**Chapter 10 Long-Term Health Issues**

§ 10:1 Uncertainty: Infection’s Likely Persistence and  
 Recurrence..... 10-1  
 § 10:2 Viral Effects Persistence Can Be Measured by  
 Antibody Testing..... 10-2  
 § 10:3 Lung Effect Consequences for Surviving Patients ..... 10-2  
 § 10:4 Susceptibility to Infections After Recovery from  
 Acute Incident ..... 10-3

*Table of Contents*

§ 10:5 Employee Refusal to Reenter Workplace ..... 10-3  
§ 10:6 Work-Related Post-COVID Disability Payments..... 10-3

**Chapter 11 Prevention and Treatment: Vaccines and Drugs**

§ 11:1 What Is a Vaccine? ..... 11-1  
§ 11:2 How Will the Vaccine Stop COVID-19? ..... 11-2  
§ 11:3 How Is a Vaccine (or Drug) Developed? ..... 11-3  
§ 11:4 How Is Marketing of a Vaccine Approved? ..... 11-4  
§ 11:5 What Could Go Wrong? ..... 11-5  
§ 11:6 Beyond Vaccines ..... 11-5  
§ 11:7 Drug Treatment for COVID-19 ..... 11-5  
§ 11:8 NIH Recommendations for Treatment—Standard  
of Care? ..... 11-6  
Table 11-1 Recommendation Rating Scheme ..... 11-7  
§ 11:9 Presentation of Symptoms for Treatment ..... 11-7  
§ 11:10 Incubation Periods ..... 11-8  
§ 11:11 Signs and Symptoms ..... 11-9  
    § 11:11.1 Asymptomatic and Pre-Symptomatic Infection .... 11-11  
    § 11:11.2 Asymptomatic and Pre-Symptomatic  
Transmission ..... 11-11

**Chapter 12 Employer Healthcare Insurance Eligibility Issues**

§ 12:1 How Much Will Hospital Treatment of COVID-19  
Patients Cost? ..... 12-1  
§ 12:2 Employer Insurance Programs Impacted by  
Coronavirus..... 12-3  
§ 12:3 Cost Burdens on Patients..... 12-4  
§ 12:4 Causes of Infection Influencing Coverage ..... 12-6  
§ 12:5 Contractual Coverages..... 12-9  
§ 12:6 Second and Subsequent Infection Costs ..... 12-10  
§ 12:7 Litigating Denials of Coverage for Harm from  
COVID-19..... 12-11  
§ 12:8 Failure of Diagnostic Efforts to Detect the Virus..... 12-12

**Chapter 13 Death Benefit Issues**

§ 13:1 Life Insurance Payment As Employee Benefit ..... 13-1  
§ 13:2 Corporate Employer COVID-19 Liability ..... 13-1  
§ 13:3 Public-Employer Compensation ..... 13-2

**Chapter 14 Business Liability Risks from On-Site Infections**

§ 14:1 Business Liability from Exposures to SARS-CoV-2 ..... 14-1  
 § 14:2 The “Invitee” and “Licensee” Status ..... 14-2  
 § 14:3 Workers’ Compensation Exclusivity ..... 14-3  
 § 14:4 Statutory Presumptions ..... 14-4  
 § 14:5 Workers’ Compensation Change Alternatives..... 14-6  
 § 14:6 OSHA “Recordable Illness” Criteria..... 14-7  
 § 14:7 OSHA and State Workers’ Compensation  
 Decisions..... 14-10  
 § 14:8 Emergency OSHA COVID-19 Standard..... 14-11  
 § 14:9 Use of Preventive Chemicals ..... 14-12  
 § 14:10 Smaller Employers (Less Than Ten Employees) ..... 14-13  
 § 14:11 Claims by Federal Employees..... 14-13

**Chapter 15 Employment Discrimination Issues**

§ 15:1 EEOC Guidance and State Workplace  
 Discrimination Standards..... 15-1  
 § 15:2 Relevant Americans with Disabilities Act (ADA)  
 Requirements During a Pandemic ..... 15-3  
 § 15:3 Disability-Related Inquiries and Medical  
 Examinations ..... 15-4  
 § 15:4 Direct Threat and COVID-19 Pandemic ..... 15-5  
 § 15:5 Reasonable Accommodation..... 15-7  
 § 15:6 Responses During a Pandemic ..... 15-7  
 § 15:7 Remedies for Disability Discrimination Issues in  
 Federal and State Law ..... 15-9  
 § 15:8 “Disability” Definition Is Changing ..... 15-9  
 § 15:9 Federal SSI Norms of “Disability” ..... 15-10  
 § 15:10 Permanent Disability Concerns for COVID-19  
 Survivors ..... 15-11

**Chapter 16 Regulatory Oversight of Tools Used to Fight  
 COVID-19**

§ 16:1 Overview of Regulatory Oversight..... 16-1  
 § 16:2 Emergency Use Authorization (EUA) Clearance ..... 16-2  
 § 16:3 Regulation of Personal Protective Equipment (PPE) ..... 16-4  
 § 16:4 Regulation of Patient Devices and Ventilators..... 16-7  
 § 16:5 Regulation of Sterilants, Disinfectants and  
 Sanitizers..... 16-11  
 § 16:6 Regulation of Medications ..... 16-14  
 § 16:7 Regulation of Diagnostic Devices ..... 16-15

*Table of Contents*

**Chapter 17 Advising About Tort Immunity in COVID-19 Claims**

§ 17:1 What Is Immunity? ..... 17-1  
§ 17:2 State Workers' Compensation..... 17-2  
§ 17:3 State Medical Immunity Laws ..... 17-2  
§ 17:4 Federal Immunity Laws ..... 17-2  
§ 17:5 The Immunity That Shields COVID-Use Products ..... 17-3

**Chapter 18 Responding to Future Client Needs**

§ 18:1 Finding Success As an Advocate During the  
Pandemic ..... 18-1  
§ 18:2 Counseling the Healthcare Providers ..... 18-2  
§ 18:3 Documentation Is Essential but Difficult ..... 18-2  
§ 18:4 Defending the Products ..... 18-3  
§ 18:5 Using the Human Resources Office Files ..... 18-3  
§ 18:6 Your Client's Readiness for Future Pandemics ..... 18-4

**Appendix A The CARES Act—Selected Provisions** ..... App. A-1

**Appendix B CDC Guidance on Antibody Testing**..... App. B-1

**Appendix C OSHA Guidance on Preparing  
Workplaces for COVID-19** ..... App. C-1

**Appendix D Equal Employment Opportunity Commission:  
What You Should Know About COVID-19  
and the ADA, the Rehabilitation Act,  
and Other EEO Laws**..... App. D-1

**Appendix E HHS Emergency Declaration** ..... App. E-1

**Appendix F FDA Emergency Use Authorization  
Guidance**..... App. F-1

**Appendix G EPA Guidance on Safe and Effective  
Disinfectant Use** ..... App. G-1

**Appendix H HHS Guidance on Interpreting  
COVID-19 Test Results**..... App. H-1

**Index**..... I-1

